Shalata W - Search Results

1

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations.

Janzic U, Shalata W, Szymczak K, Dziadziuszko R, Jakopovic M, Mountzios G, Płużański A, Araujo A, Charpidou A, Agbarya A. Janzic U, et al. Among authors: shalata w. Int J Mol Sci. 2023 Aug 16;24(16):12840. doi: 10.3390/ijms241612840. Int J Mol Sci. 2023. PMID: 37629023 Free PMC article.

2

Is alectinib-induced elevation of creatine phosphokinase a predictive factor for response? Report of two cases and review of the literature.

Shalata W, Massalha I, Agbarya A. Shalata W, et al. Anticancer Drugs. 2021 Apr 1;32(4):456-459. doi: 10.1097/CAD.0000000000001043. Anticancer Drugs. 2021. PMID: 33470619 Review.

3

Encephalitis Induced by Durvalumab During Treatment of Metastatic Small-Cell Lung Cancer: Illustrative Case and Review of the Literature.

Shechtman Y, Shalata W, Khoury R, Mahajna A, Weller B, Agbarya A. Shechtman Y, et al. Among authors: shalata w. J Immunother. 2021 Sep 1;44(7):243-247. doi: 10.1097/CJI.0000000000000362. J Immunother. 2021. PMID: 33734140 Review.

4

Metastatic small cell lung cancer - an aggressive disease: a case report and literature review.

Shalata W, Massalha I, Rouvinov K, Oscar E, Toker M, A-J A, Dudnik Y, Yakobson A. Shalata W, et al. Anticancer Drugs. 2021 Nov 1;32(10):1138-1141. doi: 10.1097/CAD.0000000000001119. Anticancer Drugs. 2021. PMID: 34232947

5

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future.

Shalata W, Jacob BM, Agbarya A. Shalata W, et al. Cancers (Basel). 2021 Aug 16;13(16):4119. doi: 10.3390/cancers13164119. Cancers (Basel). 2021. PMID: 34439273 Free PMC article. Review.

6

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future.

Szeto CH, Shalata W, Yakobson A, Agbarya A. Szeto CH, et al. Among authors: shalata w. J Clin Med. 2021 Nov 29;10(23):5614. doi: 10.3390/jcm10235614. J Clin Med. 2021. PMID: 34884316 Free PMC article. Review.

7

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?

Shalata W, Yakobson A, Steckbeck R, Jama AA, Abu Saleh O, Agbarya A. Shalata W, et al. Curr Oncol. 2021 Dec 31;29(1):173-177. doi: 10.3390/curroncol29010016. Curr Oncol. 2021. PMID: 35049690 Free PMC article.

8

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment.

Agbarya A, Shalata W, Addeo A, Charpidou A, Cuppens K, Brustugun OT, Rajer M, Jakopovic M, Marinca MV, Pluzanski A, Hiltermann J, Araújo A. Agbarya A, et al. Among authors: shalata w. J Clin Med. 2022 Mar 21;11(6):1738. doi: 10.3390/jcm11061738. J Clin Med. 2022. PMID: 35330063 Free PMC article.

9

Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.

Shalata W, Yakobson A, Weissmann S, Oscar E, Iraqi M, Kian W, Peled N, Agbarya A. Shalata W, et al. Oncology. 2022;100(9):467-474. doi: 10.1159/000525188. Epub 2022 Jun 9. Oncology. 2022. PMID: 35679833 Free article.

10

NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs.

Iraqi M, Bolel P, Sarkar R, Bhattacharya B, Abu Ahmad M, Edri A, Roisman LC, Elkabets M, Shalata W, Peled N, Porgador A. Iraqi M, et al. Among authors: shalata w. Int J Mol Sci. 2022 Nov 14;23(22):14054. doi: 10.3390/ijms232214054. Int J Mol Sci. 2022. PMID: 36430528 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters